Lead Discovery Siena

Executive Summary

Lead Discovery Siena (LDS) is an Italian SME and University of Siena spin-off that combines fee-for-service drug discovery with proprietary small molecule programs in oncology, infectious diseases, and pulmonary conditions. The company differentiates itself through integrated capabilities spanning target identification to lead optimization, leveraging AI/ML to accelerate hit-to-lead campaigns. With a pre-clinical stage, LDS aims to advance its internal pipeline toward IND-enabling studies while generating revenue through services. The hybrid model reduces capital burn and provides validation for its platform. Near-term focus is on progressing lead candidates in antifungal and oncology indications through in vivo efficacy and safety profiling. LDS’s location in Siena provides access to academic collaborations and a skilled biotech workforce.

Upcoming Catalysts (preview)

• Q4 2026In vivo efficacy data for lead antifungal candidate40% success
• H1 2027Strategic partnership for oncology program30% success
• H2 2027IND-enabling toxicology results for lead candidate25% success